Looking for a inventory that has been persistently beating earnings estimates and is perhaps effect
Looking for a inventory that has been persistently beating earnings estimates and is perhaps effectively positioned to maintain the streak alive in its subsequent quarterly report? Genomic Well being (GHDX), which belongs to the Zacks Medical – Biomedical and Genetics trade, might be a terrific candidate to contemplate.
This most cancers check maker has seen a pleasant streak of beating earnings estimates, particularly when trying on the earlier two reviews. The common shock for the final two quarters was 18.62%.
For the newest quarter, Genomic Well being was anticipated to publish earnings of $0.35 per share, nevertheless it reported $0.42 per share as a substitute, representing a shock of 20%. For the earlier quarter, the consensus estimate was $0.29 per share, whereas it really produced $0.34 per share, a shock of 17.24%.
Value and EPS Shock
Thanks partially to this historical past, there was a positive change in earnings estimates for Genomic Well being currently. In reality, the Zacks Earnings ESP (Anticipated Shock Prediction) for the inventory is…